MX2022007351A - Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos. - Google Patents
Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos.Info
- Publication number
- MX2022007351A MX2022007351A MX2022007351A MX2022007351A MX2022007351A MX 2022007351 A MX2022007351 A MX 2022007351A MX 2022007351 A MX2022007351 A MX 2022007351A MX 2022007351 A MX2022007351 A MX 2022007351A MX 2022007351 A MX2022007351 A MX 2022007351A
- Authority
- MX
- Mexico
- Prior art keywords
- oxoisoindolin
- piperidine
- methoxy
- hemoglobinopathies
- beta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
La presente divulgación se relaciona con composiciones farmacéuticas y compuestos de fórmula (I') y con su uso para reducir los niveles de expresión de los Motivos de Dedos de Zinc Ampliamente Interespaciados (WIZ), o para inducir la expresión de la hemoglobina fetal (HbF), y para el tratamiento de trastornos sanguíneos hereditarios (por ejemplo, hemoglobinopatías, por ejemplo, beta-hemoglobinopatías), tales como la enfermedad de células falciformes y la beta-talasemia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962950048P | 2019-12-18 | 2019-12-18 | |
PCT/IB2020/062070 WO2021124172A1 (en) | 2019-12-18 | 2020-12-16 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022007351A true MX2022007351A (es) | 2022-07-19 |
Family
ID=73856242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022007351A MX2022007351A (es) | 2019-12-18 | 2020-12-16 | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos. |
Country Status (20)
Country | Link |
---|---|
US (1) | US11566022B2 (es) |
EP (1) | EP4076650B1 (es) |
JP (1) | JP2023506642A (es) |
KR (1) | KR20220114065A (es) |
CN (1) | CN114828959B (es) |
AR (1) | AR120773A1 (es) |
AU (1) | AU2020410514A1 (es) |
BR (1) | BR112022011796A2 (es) |
CA (1) | CA3164832A1 (es) |
CO (1) | CO2022008243A2 (es) |
CR (1) | CR20220278A (es) |
DO (1) | DOP2022000121A (es) |
EC (1) | ECSP22055267A (es) |
IL (1) | IL293530A (es) |
JO (1) | JOP20220152A1 (es) |
MX (1) | MX2022007351A (es) |
PE (1) | PE20230159A1 (es) |
TW (1) | TW202130631A (es) |
UY (1) | UY38986A (es) |
WO (1) | WO2021124172A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY39671A (es) | 2021-03-15 | 2022-10-31 | Novartis Ag | Derivados de pirazolopiridina y sus usos. |
AU2022284366A1 (en) * | 2021-06-03 | 2023-10-26 | Novartis Ag | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof |
WO2023006097A1 (zh) * | 2021-07-30 | 2023-02-02 | 海创药业股份有限公司 | 一种双功能嵌合体杂环化合物及其作为雄激素受体降解剂的用途 |
CN115959976A (zh) * | 2022-12-30 | 2023-04-14 | 安徽诺全药业有限公司 | 一种甲氧基取代双环戊烷衍生物的制备方法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | GENESIS OF THE RNA INTERFERENCE PATH AS AID OF TARGETED GENTIAN INTERFERENCE |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
WO2002059300A2 (en) | 2000-12-28 | 2002-08-01 | J & J Research Pty Ltd | Double-stranded rna-mediated gene suppression |
WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
RS58523B1 (sr) * | 2010-02-11 | 2019-04-30 | Celgene Corp | Derivati arilmetoksi izoindolina i kombinacije koje ih obuhvataju i postupci njihove upotrebe |
WO2012068512A1 (en) | 2010-11-18 | 2012-05-24 | Deuteria Pharmaceuticals Llc | 3-deutero-pomalidomide |
WO2012079022A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
ES2755748T3 (es) | 2012-07-27 | 2020-04-23 | Celgene Corp | Procedimientos para preparar compuestos de isoindolin-1,3-diona |
JP2018523823A (ja) | 2015-08-04 | 2018-08-23 | セルジーン コーポレイション | 慢性リンパ球性白血病の治療方法及び免疫調節療法に対する臨床的感度の予測因子としてのバイオマーカーの利用 |
CN109071552B (zh) | 2016-04-22 | 2022-06-03 | 达纳-法伯癌症研究所公司 | 细胞周期蛋白依赖性激酶4/6(cdk4/6)通过cdk4/6抑制剂与e3连接酶配体的缀合的降解及使用方法 |
JP7009466B2 (ja) | 2016-10-11 | 2022-02-10 | アルビナス・オペレーションズ・インコーポレイテッド | アンドロゲン受容体の標的分解のための化合物および方法 |
MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
KR102173464B1 (ko) | 2016-12-01 | 2020-11-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES |
KR102564201B1 (ko) | 2016-12-23 | 2023-08-07 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
EP3559002A4 (en) | 2016-12-23 | 2021-02-17 | Arvinas Operations, Inc. | CHEMERICAL MOLECULES TARGETING EGFR PROTEOLYSIS AND RELATED METHODS OF USE |
US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
EP3573977A4 (en) | 2017-01-26 | 2020-12-23 | Arvinas Operations, Inc. | EESTROGEN RECEPTOR PROTEOLYSIS MODULATORS AND RELATED METHOD OF USE |
BR112020007576A2 (pt) * | 2017-10-18 | 2020-09-24 | Novartis Ag | composições e métodos para degradação de proteína seletiva |
WO2019079701A1 (en) | 2017-10-20 | 2019-04-25 | Dana-Farber Cancer Institute, Inc. | HETEROBIFUNCTIONAL COMPOUNDS HAVING IMPROVED SPECIFICITY FOR BRD4 BROMODOMAINE |
EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
US10874743B2 (en) | 2017-12-26 | 2020-12-29 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
EP3765026A4 (en) | 2018-03-10 | 2021-12-22 | Yale University | BTK PROTEOLYSIS MODULATORS AND METHODS FOR USE |
KR20210018199A (ko) * | 2018-03-26 | 2021-02-17 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스의 분해를 위한 세레블론 결합제 |
CA3095494C (en) | 2018-04-04 | 2023-11-07 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
CA3102217A1 (en) | 2018-06-29 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Bispecific degraders |
AU2019294835A1 (en) | 2018-06-29 | 2020-12-17 | Dana-Farber Cancer Institute, Inc. | Ligands to cereblon (CRBN) |
JP7328263B2 (ja) | 2018-06-29 | 2023-08-16 | ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド | 免疫調節化合物 |
US20210277018A1 (en) | 2018-06-29 | 2021-09-09 | Dana-Farber Cancer Institute, Inc. | New crbn modulators |
JP2022510313A (ja) | 2018-12-03 | 2022-01-26 | ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド | Heliosの低分子分解誘導剤および使用方法 |
-
2020
- 2020-12-16 AR ARP200103501A patent/AR120773A1/es unknown
- 2020-12-16 BR BR112022011796A patent/BR112022011796A2/pt not_active Application Discontinuation
- 2020-12-16 JO JOP/2022/0152A patent/JOP20220152A1/ar unknown
- 2020-12-16 CA CA3164832A patent/CA3164832A1/en active Pending
- 2020-12-16 TW TW109144481A patent/TW202130631A/zh unknown
- 2020-12-16 CN CN202080087049.9A patent/CN114828959B/zh active Active
- 2020-12-16 PE PE2022001098A patent/PE20230159A1/es unknown
- 2020-12-16 CR CR20220278A patent/CR20220278A/es unknown
- 2020-12-16 US US17/124,127 patent/US11566022B2/en active Active
- 2020-12-16 JP JP2022537250A patent/JP2023506642A/ja active Pending
- 2020-12-16 WO PCT/IB2020/062070 patent/WO2021124172A1/en active Application Filing
- 2020-12-16 MX MX2022007351A patent/MX2022007351A/es unknown
- 2020-12-16 IL IL293530A patent/IL293530A/en unknown
- 2020-12-16 AU AU2020410514A patent/AU2020410514A1/en active Pending
- 2020-12-16 EP EP20828350.7A patent/EP4076650B1/en active Active
- 2020-12-16 UY UY0001038986A patent/UY38986A/es unknown
- 2020-12-16 KR KR1020227024287A patent/KR20220114065A/ko active Search and Examination
-
2022
- 2022-06-13 CO CONC2022/0008243A patent/CO2022008243A2/es unknown
- 2022-06-14 DO DO2022000121A patent/DOP2022000121A/es unknown
- 2022-07-14 EC ECSENADI202255267A patent/ECSP22055267A/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220114065A (ko) | 2022-08-17 |
CN114828959B (zh) | 2024-04-02 |
UY38986A (es) | 2021-07-30 |
JP2023506642A (ja) | 2023-02-17 |
CN114828959A (zh) | 2022-07-29 |
CA3164832A1 (en) | 2021-06-24 |
TW202130631A (zh) | 2021-08-16 |
WO2021124172A1 (en) | 2021-06-24 |
EP4076650B1 (en) | 2024-02-28 |
US11566022B2 (en) | 2023-01-31 |
EP4076650A1 (en) | 2022-10-26 |
BR112022011796A2 (pt) | 2022-08-30 |
DOP2022000121A (es) | 2022-08-15 |
AR120773A1 (es) | 2022-03-16 |
JOP20220152A1 (ar) | 2023-01-30 |
IL293530A (en) | 2022-08-01 |
AU2020410514A1 (en) | 2022-06-30 |
US20220402904A1 (en) | 2022-12-22 |
PE20230159A1 (es) | 2023-02-01 |
CR20220278A (es) | 2022-07-01 |
ECSP22055267A (es) | 2022-08-31 |
CO2022008243A2 (es) | 2022-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022007351A (es) | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos. | |
CY1113766T1 (el) | Παραγωγα ινδολιδονης για την θεραπεια ή προληψη ινωτικων ασθενειων | |
MX2011010859A (es) | Peptidos utiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosmeticas o farmaceuticas. | |
MY140488A (en) | Substituted oxazolidinones and their use in the field of blood coagulation | |
EA200600076A1 (ru) | Композиции и способы увеличения активности теломеразы | |
PT2150530E (pt) | Derivados de sulfonamida substituídos | |
TW200612903A (en) | Use of trisubstituted benzopyranones | |
EA200971107A1 (ru) | Катехоламиновые производные, полезные для лечения болезни паркинсона | |
MX2019013561A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
MY146403A (en) | F, g, h, i and k crystal forms of imatinib mesylate | |
TW200731975A (en) | Novel combinations of medicaments for the treatment of respiratory diseases | |
WO2013061004A8 (fr) | Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines | |
BR112012028321A2 (pt) | "compostos análogos de desazadesferrotiocina e desazadesferrotiocina poliéter como agentes de quelação de metal, composição farmacêutica e usos dos ditos compostos" | |
ATE451922T1 (de) | Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren | |
BR112014028813A2 (pt) | 5-amino[1,4]tiazinas como inibidores bace1 | |
TW200510352A (en) | Cycloalkyl substituted amino acid derivatives, processes for their freparation and their use as pharmaceuticals | |
CO2024000013A2 (es) | Derivados de 3–(1–oxoisoindolin–2–il)piperidina–2,6–diona y sus usos médicos | |
IN2011KN05169A (es) | ||
ATE422892T1 (de) | Verwendung von hyaluronsäure zur herstellung von zusammensetzungen zur behandlung rekurrenten aphthen in der mundhöhle | |
DE59909607D1 (de) | Tan-1057 derivate | |
NO20053876D0 (no) | Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav | |
WO2006087147A3 (en) | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia | |
UA94596C2 (ru) | N-сульфамоил-n'-бензопиранпиперидины, предназначенные для применения в медицине | |
SG11201806628UA (en) | New bi-aromatic propynyl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof | |
ECSP23076800A (es) | Derivados de pirazolopiridina y sus usos |